-
Watch 5 Stocks: Molina Healthcare (NYSE:MOH), Electromed (NYSEMKT:ELMD), Enanta Pharmaceuticals (NASDAQ:ENTA), THT Heat Transfer Technology (NASDAQ:THTI), Exelixis (NASDAQ:EXEL)
Molina Healthcare (NYSE:MOH), swung to a net profit for the quarter ended Dec. 31, 2014. The company has made a net profit of $33.79 million, or $ 0.69 a share in the quarter, against a net loss of $9.13 million, or $0.20 a share in the last year period. On Tuesday shares of Molina Healthcare,…
-
Active Movers: Enanta Pharmaceuticals (NASDAQ:ENTA), Pfizer Inc. (NYSE:PFE), MoSys (NASDAQ:MOSY), Capital City Bank Group Inc. (NASDAQ:CCBG)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CFO Paul J. Mellett sold 4,500 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $49.45, for a total transaction of $222,525.00. Following the completion of the transaction, the chief financial officer now directly owns 121,897 shares…
-
Stock Highlights: Inovio Pharmaceuticals (NASDAQ:INO), Under Armour (NYSE:UA), Opko Health (NYSE:OPK), Hospira Inc. (NYSE:HSP), Enanta Pharmaceuticals (NASDAQ:ENTA)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that President and CEO, Dr. J. Joseph Kim will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9 at 9:30 AM ET at The Waldorf Astoria in New York, NY. On Wednesday shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) closed at $8.03. Company’s…
-
Biotech Top Losers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), Pacific Biosciences of California (NASDAQ:PACB), Celldex Therapeutics (NASDAQ:CLDX), Enanta Pharmaceuticals (NASDAQ:ENTA)
Gilead Sciences Inc. (NASDAQ:GILD) reported Total revenues of $7.3 billion were no comparison to the year-ago figure of $3.1 billion. Quarterly revenues were above the Zacks Consensus Estimate of $6.7 billion. Full-year 2014 revenues increased 122.2% to $24.9 billion, topping the Zacks Consensus Estimate of $24.3 billion. Earnings (including stock-based compensation expenses) increased to $7.91…
-
Biotech Bears: Amicus Therapeutics (NASDAQ:FOLD), Genetic Technologies Limited (NASDAQ:GENE), Ardelyx (NASDAQ:ARDX), Enanta Pharmaceuticals (NASDAQ:ENTA), Spark Therapeutics (NASDAQ:ONCE)
Amicus Therapeutics (NASDAQ:FOLD), announced that 2 oral presentations and 6 posters highlighting its development programs for lysosomal storage diseases will be included at the 11th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 9-13, 2015 in Orlando, FL.On Monday shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed at $7.24. Company’s sales growth…
-
Top Movers: Wells Fargo (NYSE:WFC), Enanta Pharmaceuticals (NASDAQ:ENTA), Merck & Co. Inc. (NYSE:MRK), Northern Technologies International Corp. (NASDAQ:NTIC), Rite Aid (NYSE:RAD)
A U.S. judge on Monday rejected allegations by the New York state attorney general that Wells Fargo & Company (NYSE:WFC) was not complying with the $25 billion mortgage settlement that federal and state authorities reached with five banks in 2012. On Monday shares of Wells Fargo & Company (NYSE:WFC) closed at $52.81. Company’s sales growth…
-
Top Biotech Losers: Advaxis (NASDAQ:ADXS), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Otonomy (NASDAQ:OTIC), Enanta Pharmaceuticals (NASDAQ:ENTA), FibroGen (NASDAQ:FGEN)
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. On Thursday shares of Advaxis, Inc. (NASDAQ:ADXS)…
-
Why Trader’s Are Watching: Comcast Corporation (NASDAQ:CMCSA), Huntington Bancshares Incorporated (NASDAQ:HBAN), Parker Drilling Co. (NYSE:PKD), Mitel Networks Corporation (NASDAQ:MITL), Enanta Pharmaceuticals (NASDAQ:ENTA)
Comcast Corporation (NASDAQ:CMCSA) has said it would like to develop new service offerings that provide higher bandwidth to certain companies, something consumers worry would lead to the death of Internet freedom. Labeling the Internet as a public utility would prevent that.On Tuesday shares of Comcast Corporation (NASDAQ:CMCSA) closed at $55.81. Company’s sales growth for last…
-
Hot Watch List: Enanta Pharmaceuticals (NASDAQ:ENTA), Encana Corporation (NYSE:ECA), Amber Road (NYSE:AMBR), Avino Silver & Gold Mines (NYSEMKT:ASM), MGIC Investment (NYSE:MTG)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), said the European Commission has granted marketing authorizations for AbbVie’s VIEKIRAX + EXVIERA with or without ribavirin or RBV for the treatment of patients with genotype 1 or GT1 chronic hepatitis C virus or HCV infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver…
-
Must Watch These 5 Stocks: Merck. (NYSE:MRK), Enanta Pharmaceuticals (NASDAQ:ENTA), Koninklijke Philips (NYSE:PHG), Cepheid (NASDAQ:CPHD), Span-America Medical Systems (NASDAQ:SPAN)
On Dec 22, Merck & Co. Inc. (NYSE:MRK) $9.5 billion Cubist buyout got off to a rocky start when a U.S. court nixed all but one patent covering top-seller Cubicin. And now, it’ll be up to brand-new FDA approval Zerbaxa to turn things around. Merck & Co. Inc. (NYSE:MRK) in last trading activity moved up…